Efficacy of Acceptance and Commitment Therapy on Impulsivity and Suicidality Among Clients With Bipolar Disorders

January 11, 2023 updated by: ayman el-ashry, Alexandria University

The Efficacy of Acceptance and Commitment Therapy on Impulsivity and Suicidality Among Clients With Bipolar Disorders: A Randomized Controlled Trial

Psychiatric nurses face a huge challenge in predicting and preventing suicide behaviour in their patients with bipolar disorders, but it may also be one of the most accurate measures of how well their clinical care is working. In addition to, high impulsivity scores are associated with increased overall functional impairment, a higher number of episodes with early onset, and a higher number of past suicide attempts, as well as increased substance intake. Thus, this study aimed at evaluating the efficacy acceptance and commitment therapy on impulsivity and suicidality among bipolar clients.

research hypnosis

  • Clients who engaged in acceptance and commitment therapy had less impulsivity than the control group.
  • Clients who engaged in acceptance and commitment therapy had less suicidality than the control group.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Alexandria, Egypt, 002
        • Faculty of Nursing

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Clients had to be at least 18 years old
  • able to converse intelligibly and meaningfully
  • read and write
  • have an illness that hadn't lasted more than 10 years to assure the client's functionality
  • ready to take part in the study.

Exclusion Criteria:

  • Clients who demonstrated psychotic symptoms
  • attended another group sessions
  • were intoxicated or under the influence of alcohol
  • had any comorbidity were excluded from this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: patients with bipolar disorder who will partaicpmg in acceptance and commitment therapy
patients with bipolar disorder who will participate in acceptance and commitment therapy
Behavioral: acceptance and commitment therapy
ACT attempts to encourage psychological flexibility, acceptance of one's own experiences, and dedication to behaviours that are consistent with one's own values. ACT therapies focus on six key processes to improve psychological flexibility: engagement with the present moment, acceptance, defusion, self as context, values clarification, and committed action.
Placebo Comparator: patients with bipolar disorder who will be under routine hospital care
Other: routine hospital care
the patients with bipolar disorders who receive routine pharmacological treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Impulsivity
Time Frame: up to 16 weeks
This questionnaire has 20 items that assess five aspects of impulsivity: positive eagerness, negative urgency, lack of perseverance, lack of premeditation, and sensation seeking. Each of the five aspects is evaluated using four items on a four-point Likert scales with anchors 1 (=Strongly agree) and 4 (=Strongly disagree). An elevated prevalence of impulsivity is reflected in higher scores.To create the Arabic S-UPPS-P, investigators had a professional translator translate the original S-UPPS-P's items from English into Arabic, and then back-translated into Arabic.
up to 16 weeks
Suicide Ideation
Time Frame: up to 16 weeks
BSSI is a 19-item scale that assesses the presence and intensity of suicidal thoughts in the week before examination. Each item is rated on an ordinal scale of 0 to 2, and the total score ranges from 0 to 38. Individuals respond to the first five things that are excerpted. If an individual replies positively to the fifth item (scores 1 and 2), he or she answers the remaining items; otherwise, the questionnaire is finished. There was no cut-off point utilised to classify the scores. As a result, for data analysis, investigators used overall scale scores.The more score increased, the more the client vulnerable to suicide.
up to 16 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Alexandria University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 15, 2022

Primary Completion (Actual)

November 15, 2022

Study Completion (Actual)

December 20, 2022

Study Registration Dates

First Submitted

December 25, 2022

First Submitted That Met QC Criteria

January 11, 2023

First Posted (Actual)

January 23, 2023

Study Record Updates

Last Update Posted (Actual)

January 23, 2023

Last Update Submitted That Met QC Criteria

January 11, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB00013620/64/9/2022

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bipolar Disorder

Clinical Trials on acceptance and commitment therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe